CYTOSORBENTS CORPORATION Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
CYTOSORBENTS CORPORATION (CTSO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $3.81 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.49, a 33.78% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $5.27, a 0.96% increase year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $5.22, a 9.89% increase year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $4.75, a 36.50% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $5.54, a 3.75% increase from fiscal 2024.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $5.34, a 4.81% decline from fiscal 2023.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $5.61, a 27.24% decline from fiscal 2022.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $7.71, a 3.35% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $3.81 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $3.49 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $5.54 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $6.15 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $6.64 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | $5.27 10-Q · filed 2025-05-14 | ||||
| 2024-12-31 | $5.34 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $5.40 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $5.31 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | $5.22 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | $5.61 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $5.10 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $4.95 10-Q · filed 2023-08-01 | ||||
| 2023-03-31 | $4.75 10-Q · filed 2023-05-02 | ||||
| 2022-12-31 | $7.71 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $8.14 10-Q · filed 2022-11-03 | ||||
| 2022-06-30 | $8.66 10-Q · filed 2022-08-02 | ||||
| 2022-03-31 | $7.48 10-Q · filed 2022-05-03 | ||||
| 2021-12-31 | $7.46 10-K · filed 2024-03-15 | ||||
| 2021-09-30 | $8.13 10-Q · filed 2021-11-04 | ||||
| 2021-06-30 | $6.94 10-Q · filed 2021-08-03 | ||||
| 2020-12-31 | $5.60 10-K · filed 2023-03-09 | ||||
| 2020-09-30 | $5.60 10-Q · filed 2020-11-04 | ||||
| 2020-06-30 | $5.57 10-Q · filed 2020-08-04 | ||||
| 2020-03-31 | $5.76 10-Q · filed 2020-05-05 | ||||
| 2019-12-31 | $4.16 10-K · filed 2022-03-10 | ||||
| 2019-09-30 | $4.20 10-Q · filed 2019-11-05 | ||||
| 2019-06-30 | $4.20 10-Q · filed 2019-08-06 | ||||
| 2019-03-31 | $4.20 10-Q · filed 2019-05-07 | ||||
| 2018-12-31 | $2.88 10-K · filed 2021-03-09 | ||||
| 2018-09-30 | $2.88 10-Q · filed 2018-11-06 | ||||
| 2018-06-30 | $2.88 10-Q · filed 2018-08-02 | ||||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 | ||||
| 2017-12-31 | $34.61 10-K · filed 2020-03-05 | ||||
| 2017-09-30 | $36.33 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $36.33 10-Q · filed 2017-08-07 | ||||
| 2017-03-31 | $36.33 10-Q · filed 2017-05-08 | ||||
| 2016-12-31 | $114.33 10-K · filed 2019-03-07 | ||||
| 2016-09-30 | $121.85 10-Q · filed 2016-11-07 | ||||
| 2016-06-30 | $31.25 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | $31.25 10-Q · filed 2016-05-09 | ||||
| 2015-12-31 | $0.00 10-K · filed 2018-03-08 | ||||
| 2014-12-31 | $45.80 10-K · filed 2017-03-03 | ||||
| 2013-12-31 | $192.75 10-K · filed 2015-03-31 | $7.71 10-K · filed 2014-03-31 | |||
| 2012-12-31 | $34.72 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |